Identification of Chikusetsusaponin IVa as a Novel Lysine-Specific Demethylase 1 Inhibitor That Ameliorates High Fat Diet-Induced MASLD in Mice

Researchers investigated the beneficial effects of chikusetsusaponin IVa (CHS) on metabolic dysfunction steatotic liver disease (MASLD) and the underlying mechanisms. MAFLD mouse model was established by the high-fat diet for 6 weeks and then were treated with CHS for another 8 weeks.